Sort
4,870 grants matching “glp 1”
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia
$680,821Anastasia Khvorova · Univ Of Massachusetts Med Sch Worcester · R01 · FY2018 · HD
Brain systems and behaviors underlying response to obesity treatment in children
$680,326Christian Ludwig Roth · Seattle Children'S Hospital · R01 · FY2020 · DK
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed
$680,041Rafal A Farjo · Charlesson, Llp · R44 · FY2013 · EY
Development of Anorexigenic and Glucoregulatory Chimeric Peptides
$680,023Christian Ludwig Roth · Seattle Children'S Hospital · R01 · FY2023 · DK
Glucagon Mini-Dosing Pen for Treatment of Hypoglycemia
$678,969John Kinzell · Xeris Pharmaceuticals, Inc. · R44 · FY2013 · DK
Cardiovascular effects of GLP-1 in obesity/metabolic syndrome
$678,907Johnathan D Tune · Indiana University Indianapolis · R01 · FY2013 · HL
A Novel Recombinant Protein Vaccine Against Ricin Toxin
$678,824University Of Texas Sw Med Ctr/Dallas · U01 · FY2005 · AI
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy
$678,626Samarendra Kumar Mohanty · Nanoscope Technologies, Llc · R44 · FY2021 · EY
Novel Inhibitors of Lysine Methyltransferases G9a and GLP for the Treatment of Alzheimer's Disease
$678,549Jian Jin · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · AG
Advancing ADPKD Treatment with GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism
$677,909Kristen Lynn Nowak · University Of Colorado Denver · R01 · FY2025 · DK
PTE-based drug for antibiotic-resistant anthrax
$675,544Protez Pharmaceuticals, Inc. · U01 · FY2003 · AI
Manufacturing and Toxicology Studies of DNA and Protein Vaccines
$675,294Gary R Ostroff · Univ Of Massachusetts Med Sch Worcester · U19 · FY2010 · AI
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis
$675,079Wesley C Van Voorhis · University Of Washington · R01 · FY2025 · HD
Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis
$674,963Terry L Bowlin · Microbiotix, Inc · R33 · FY2025 · EY
Preclinical safety studies
$674,641William A. Beltran · University Of Pennsylvania · R24 · FY2016 · EY
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma
$674,537Timothy A Marlowe · Faknostics, Llc · R42 · FY2021 · CA
Development of Anorexigenic and Glucoregulatory Chimeric Peptides
$674,227Christian Ludwig Roth · Seattle Children'S Hospital · R01 · FY2025 · DK
Aging Intervention Studies
$673,491Julie Mattison · National Institute On Aging · ZIA · FY2015 · AG
Preclinical Evaluation of an SCN8A-directed Splice Modulating Oligonucleotide to Treat Dravet Syndrome
$673,232Nicole M Lykens · Lifesplice Pharma, Llc · U44 · FY2019 · NS
Optimization of Substituted Phenoxyalkyl Pyridinium Oximes as Therapies for Organophosphate Poisoning
$672,916Janice E. Chambers · Mississippi State University · U01 · FY2023 · NS
Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p
$672,768Angela Marie Pollard · Agile Sciences, Inc. · R42 · FY2014 · AI
Microtubule Regulation of Pancreatic Beta Cell Function and Diabetes
$672,171Irina Kaverina · Vanderbilt University · R01 · FY2021 · DK
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.
$672,124Andrea Bridget Kelly · Children'S Hosp Of Philadelphia · R01 · FY2023 · DK
Pharmacogenetics of the Response to a GLP1R Agonist
$672,029Simeon I Taylor · University Of Maryland Baltimore · R01 · FY2022 · DK
Pharmacogenetics of the Response to a GLP1R Agonist
$672,029Amber L Beitelshees · University Of Maryland Baltimore · R01 · FY2023 · DK